Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease
Real-world healthcare data hold the potential to identify therapeutic solutions for progressive diseases by efficiently pinpointing safe and efficacious repurposing drug candidates. This approach circumvents key early clinical development challenges, particularly relevant for neurological diseases,...
Main Authors: | Daphna Laifenfeld, Chen Yanover, Michal Ozery-Flato, Oded Shaham, Michal Rosen-Zvi, Nirit Lev, Yaara Goldschmidt, Iris Grossman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.631584/full |
Similar Items
-
Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
by: František Cibulcik, et al.
Published: (2016-12-01) -
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
by: John Paul Maurice Finberg, et al.
Published: (2016-10-01) -
Rasagiline-Induced Hypoglycemia
by: Nurhan Bilen, et al.
Published: (2016-12-01) -
The role of rasagiline in the treatment of Parkinson’s disease
by: Julie Leegwater-Kim, et al.
Published: (2010-05-01) -
Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®)
by: M. R. Nodel
Published: (2011-09-01)